Carboplatin

Generic Name
Carboplatin
Brand Names
Paraplatin
Drug Type
Small Molecule
Chemical Formula
C6H12N2O4Pt
CAS Number
41575-94-4
Unique Ingredient Identifier
BG3F62OND5
Background

Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication

Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions
Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
Associated Therapies
Conditioning regimens for allogeneic stem cell transplantation therapy
Clinical Trials
Related News

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

First Posted Date
2023-04-10
Last Posted Date
2024-07-08
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
44
Registration Number
NCT05806515
Locations
🇺🇸

Mercy Cancer Center �� Carmichael, Carmichael, California, United States

🇺🇸

Mercy San Juan Medical Center, Carmichael, California, United States

🇺🇸

City of Hope at Irvine Lennar, Irvine, California, United States

and more 130 locations

A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

First Posted Date
2023-04-05
Last Posted Date
2023-04-05
Lead Sponsor
Guangzhou Gloria Biosciences Co., Ltd.
Target Recruit Count
424
Registration Number
NCT05798819
Locations
🇨🇳

Fudan University Shanghai Cancer Hospital, Shanghai, Shanghai, China

Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC

First Posted Date
2023-04-05
Last Posted Date
2023-04-05
Lead Sponsor
Guangdong Provincial People's Hospital
Target Recruit Count
30
Registration Number
NCT05800340
Locations
🇨🇳

Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guanzhou, Guangdong, China

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

First Posted Date
2023-04-05
Last Posted Date
2024-03-26
Lead Sponsor
Fox Chase Cancer Center
Target Recruit Count
280
Registration Number
NCT05800587
Locations
🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

First Posted Date
2023-04-05
Last Posted Date
2024-11-14
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
950
Registration Number
NCT05800015
Locations
🇺🇸

Crosson Cancer Institute, Fullerton, California, United States

🇺🇸

University of Illinois, Chicago, Illinois, United States

🇺🇸

Arizona Clinical Research Center, Tucson, Arizona, United States

and more 67 locations

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

First Posted Date
2023-04-04
Last Posted Date
2024-12-10
Lead Sponsor
AstraZeneca
Target Recruit Count
396
Registration Number
NCT05797168
Locations
🇬🇧

Research Site, Sutton, United Kingdom

Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer

First Posted Date
2023-04-03
Last Posted Date
2023-07-20
Lead Sponsor
Aston Sci. Inc.
Target Recruit Count
98
Registration Number
NCT05794659
Locations
🇺🇸

University of Washington, Seattle, Washington, United States

Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.

First Posted Date
2023-03-30
Last Posted Date
2023-07-24
Lead Sponsor
Novartis Pharmaceuticals
Registration Number
NCT05791097

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

First Posted Date
2023-03-29
Last Posted Date
2024-11-29
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
96
Registration Number
NCT05789082
Locations
🇺🇸

MD Anderson Cancer Center; Oncology, Houston, Texas, United States

🇺🇸

UCSD Moores Cancer Center, La Jolla, California, United States

🇺🇸

Yale Cancer Center, New Haven, Connecticut, United States

and more 57 locations

A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

First Posted Date
2023-03-20
Last Posted Date
2024-11-20
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
180
Registration Number
NCT05775289
Locations
🇲🇽

ONCARE Viaducto Napoles, Ciudad de México, Mexico CITY (federal District), Mexico

🇪🇸

Hospital Son Llatzer, Palma de Mallorca, Islas Baleares, Spain

🇦🇺

Monash Health, Clayton, Victoria, Australia

and more 50 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy